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Background: Suprachoroidal hemorrhages are a vision-threatening complication, and poor 
visual outcome is correlated with increasing hemorrhage complexity. The recommended time 
of surgical drainage is 10–14 days after the hemorrhage begins to liquefy. We describe a case 
in which recombinant tissue plasminogen activator (r-tPA), alteplase, is injected within the 
suprachoroidal space before surgery to assist in the drainage of an organized clot prior to 
  liquefaction. This is a report of a technique in which r-tPA is used in the intrachoroidal space 
to target the organized clot of suprachoroidal hemorrhage prior to drainage.
Case report: A 62-year-old male presented 12 days after retinal detachment repair with   sudden 
ocular pain and vision loss after a Valsalva maneuver. Vision was light perception only, and 
intraocular pressure was 43 mmHg. Diagnosed with hyphema and suprachoroidal   hemorrhage, 
the patient underwent surgery the following day. An injection of r-tPA 100 µg was given 
  intracamerally, and an additional dose of r-tPA 100 µg was injected into the suprachoroidal 
space prior to surgery. Liquified by r-tPA, the clot was expressed through the sclerotomies. 
Best corrected vision in the eye eight months after the drainage procedure was 20/40.
Conclusion: To the author’s knowledge, this is the first reported case in which r-tPA was 
  successfully injected in the suprachoroidal space to liquefy and drain a suprachoroidal 
  hemorrhage prior to natural dissolution.
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Introduction
Suprachoroidal hemorrhage is a vision-threatening complication associated with 
certain surgical procedures, such as cataract extraction, glaucoma filtering surgery, 
penetrating keratoplasty, and retinal detachment repair.1–4 Suprachoroidal hemor-
rhage has also been reported to occur with penetrating trauma, choroidal melanoma, 
and may even occur spontaneously from corneal perforation secondary to infection.5 
  Generally, suprachoroidal hemorrhage has a guarded prognosis and poor visual 
outcome is   correlated with increasing hemorrhage complexity.6 In one study, only 
35% of eyes had a final visual acuity of at least 5/200.6 Visual rehabilitation is often 
limited and severe visual loss may be the final result. Surgical drainage is a topic of 
much controversy, but may be advocated in cases where suprachoroidal hemorrhage 
is accompanied by retinal detachment, central choroidal apposition, retinal or vitreous 
incarceration in the   surgical wound, persistent flat chamber, extreme pain, uncontrolled 
intraocular pressure, or inability to reposition intraocular contents.7–9 A suggested time 
for surgical drainage is said to be 10–14 days when the hemorrhagic clot begins to 
liquefy.10 If adequate thrombolysis could be achieved earlier, retinal complications may Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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be   prevented or reduced.   Pharmacologic clearance of the clot 
could   accelerate   clearance of the hemorrhage and potentially 
reduce serious retinal complications. We describe the use 
of the recombinant tissue plasminogen activator (r-tPA), 
alteplase, injected within the suprachoroidal space prior to 
surgery to assist in drainage of suprachoroidal hemorrhage.
Case report
A 62-year-old male underwent vitrectomy for retinal 
  detachment repair. Twelve days after surgery, the patient 
attended the clinic with severe eye pain and vision loss 
immediately after an episode of vomiting. At the time of 
examination, vision was light perception only and intraocular 
pressure was 43 mmHg. The patient had a dense anterior 
chamber hyphema and massive hemorrhagic choroidal 
detachment detected via B-scan ultrasonography. The patient 
was scheduled for surgical drainage the following day.
At the beginning of surgery, r-tPA 100 µg was injected 
into the anterior chamber and an additional r-tPA 100 µg was 
injected into the suprachoroidal space. Prior to performing 
conjunctival peritomy, a period of 15 minutes was allotted for 
clot dissolution with r-tPA. Conjunctival peritomy was then 
performed and the rectus muscles were isolated. An anterior 
chamber maintainer was placed inferotemporally. Anterior 
chamber washout was performed. Posterior sclerotomies were 
created in two quadrants to drain the hemorrhage. Approxi-
mately 45 minutes passed from the time of the initial injection 
of the r-tPa and actual drainage. Liquified by the r-tPA, the 
previously organized clot was expressed through the scleroto-
mies. A light pipe and vitrector were inserted for intravitreal 
washout. Liquid perfluorocarbon was used to assist in the 
drainage process and flatten choroidals from within the eye. 
The sclerotomies were closed with interrupted 7-0 Vicryl 
sutures. Two air-fluid exchanges were performed, followed 
by an air-silicone exchange. 5000-Centistoke   silicone oil was 
used at the end of the procedure. The oil was removed five 
months after the procedure. Best corrected vision in the eye 
eight months after the drainage procedure and three months 
after oil removal was 20/40.
Discussion
Generally, suprachoroidal hemorrhage is associated with poor 
vision. Poor outcome has been associated with retinal detach-
ment at presentation, vitreous incarceration in the wound, and 
a 360° hemorrhage.6 As the complexity of the suprachoroidal 
hemorrhage increases, any associated   retinal detachment 
is more difficult to fix.11 In addition, as the severity of the 
hemorrhage increases, it is associated with greater anatomic 
disruption, inflammation, and release of proliferative vitreo-
retinopathy precursor cells.11 Hypotony is a significant problem 
and also appears to be associated with the degree of hemor-
rhage complexity, and may be due to hemorrhagic necrosis of 
the ciliary body.12 Hypotony and increased ciliary body atrophy 
has been noted at 14 days in conjunction with hemorrhagic 
detachment of the ciliary body. Indications for surgery may 
include marked retinal   apposition due to massive choroidal 
detachment,   involvement of the macular area by hemorrhage, 
retinal detachment, central choroidal apposition, retinal or 
vitreous   incarceration in the wound, persistent flat chamber, 
extreme pain, and   uncontrolled intraocular pressure.13
There is some disagreement as to when surgery should be 
performed. Some authors suggest waiting 10–14 days for the 
clot to liquefy prior to any surgical intervention, 10,14 whereas 
others advocate early surgical intervention for better anatomic 
and visual outcome.13 While waiting for the clot to liquefy, trac-
tional retinal detachment may occur. Where there is vitreous 
incarceration, waiting for spontaneous resolution could result 
in the formation of giant retinal tears and rhegmatogenous 
detachment secondary to traction on the incarcerated vitre-
ous. In cases of extensive hemorrhage, patients have sustained 
vision loss from chronic atrophy or phtisis bulbi in the absence 
of prompt surgical intervention. As such, prompt drainage 
may provide the best chance for maintaining useful vision.15 
However, when early drainage is performed, repeated surgical 
procedures are often necessary to drain the hemorrhage.
r-tPA is a naturally occurring thrombolytic enzyme which 
activates fibrin-bound plasminogen to plasmin.16 When infused 
intravenously, the half-life of r-tPA is a few minutes. r-tPA 
has a high specific affinity for fibrin and enhances the binding 
of plasminogen to a fibrin clot. The enzyme acts selectively 
without inducing a systemic coagulation response.16 r-tPA 
has been effective in clearing hyphema, intraocular fibrin, 
vitreous hemorrhage, retinal vein   occlusion, and subretinal 
hemorrhage.17–20 In an experimental study involving rabbits, 
conducted by Kwon et al, suprachoroidal hemorrhages were 
created in rabbit eyes and randomized for treatment with a 
surgical sponge soaked with r-tPA. Clot dissolution started 
within minutes in the treated eyes, whereas days passed prior 
to the clot dissolving in the control eyes.21 Another study, 
conducted by Liu et al, evaluated the use of intravenous r-tPA 
in rabbits with suprachoroidal hemorrhages and found that 
intravenous r-tPA accelerated the clearance of the suprachor-
oidal hemorrhage when compared with control eyes.22
In our case, r-tPA 100 µg was injected into the suprachor-
oidal space in the operating room prior to the surgery. Another 
potential method for injecting r-tPA into the suprachoroidal Clinical Ophthalmology
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space preoperatively is using B-scan ultrasonography to guide 
the injection. This procedure is easier with two people, ie, 
one person holds the ultrasound probe (Figure 1), while the 
other performs the injection. The patient can then undergo the 
drainage procedure later that day or the following day.
In the experimental setting, a suprachoroidal hemorrhage 
is treated with intravenous or subconjunctival r-tPA.21,22 
Systemic tissue plasminogen activator is associated with sig-
nificant systemic risks including intracranial hemorrhage.23,24 
Directly targeting the clot with suprachoroidal r-tPA, as in 
this case report, would aid in early liquefaction and allow for 
easier expression of the hemorrhage through sclerotomies 
regardless of the time of drainage, with fewer systemic con-
sequences. Based on this case study, in which our patient had 
a fortunate outcome, it is our hypothesis that further study 
is warranted   regarding the use of r-tPA in the treatment of 
suprachoroidal hemorrhage.
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Figure  1  B-scan  ultrasound  image  of  a  patient  with  extensive  suprachoroidal 
hemorrhage secondary to tube shunt procedure treated with suprachoroidal r-tPA 
the day before surgery. Notice the dome shaped appearance and central apposition 
of  detached  choroid  (yellow  arrows).  Shadow  of  glaucoma  tube  shunt  (brown 
arrow). Optic nerve shadow (green arrow).